PurposeThis study aims to describe factors associated to treatment continuity and psychiatric relapses in patients treated with Long Acting Injectable antipsychotics (LAIs) in Bologna Community Mental Health Centers (CMHCs).MethodsNew LAI treatments administered between July 1, 2010 and June 30, 2015 in CMHCs were selected. The cohort was followed-up for 6 months; predictors of continuity and psychiatric admissions were investigated by using logistic regression- and Cox- analysis respectively.ResultsAmong the cohort of 1 070 patients, only 222 (21%) continued LAI treatment during the follow-up. LAI continuity was higher with first generation agents (OR: 1.71, 95%CI 1.18-2.49) and in case of previous psychiatric hospitalizations (OR 2.00, 95...
AbstractObjectiveAs psychopathology and social functioning can worsen with repeated psychotic episod...
BACKGROUND:For many years, long-acting intramuscular (LAI) antipsychotics have been prescribed predo...
Background/PurposeThe debate on whether long-acting injectable antipsychotic (LAIA) medication is su...
Purpose This study aims to describe factors associated to treatment continuity and psychiatric relap...
Aim & Background: Non-adherence to antipsychotic treatment is a major issue in the management of...
The aim of this study was to evaluate discontinuation and hospitalization rates in patients with sch...
Treatment discontinuation is a major challenge in routine clinical settings. Despite poor adherence ...
Antipsychotic long-acting injectable (LAI) medication has an important place as a treatment option i...
Antipsychotic long-acting injectable (LAI) medication has an important place as a treatment option i...
Non-adherence remains a significant problem in schizophrenia treatment. Discontinuation of treatment...
Schizophrenia is a relapsing and evolving condition, which requires treatment continuity. Increasing...
AIM & BACKGROUND Non-adherence to antipsychotic treatment is a major issue in the management of seve...
Scientific background. Long-acting injectable antipsychotics (LAIs) are considered one of the most i...
Although response to treatment for the first episode of schizophrenia is generally favourable, nonad...
For many years, long-acting intramuscular (LAI) antipsychotics have been prescribed predominantly to...
AbstractObjectiveAs psychopathology and social functioning can worsen with repeated psychotic episod...
BACKGROUND:For many years, long-acting intramuscular (LAI) antipsychotics have been prescribed predo...
Background/PurposeThe debate on whether long-acting injectable antipsychotic (LAIA) medication is su...
Purpose This study aims to describe factors associated to treatment continuity and psychiatric relap...
Aim & Background: Non-adherence to antipsychotic treatment is a major issue in the management of...
The aim of this study was to evaluate discontinuation and hospitalization rates in patients with sch...
Treatment discontinuation is a major challenge in routine clinical settings. Despite poor adherence ...
Antipsychotic long-acting injectable (LAI) medication has an important place as a treatment option i...
Antipsychotic long-acting injectable (LAI) medication has an important place as a treatment option i...
Non-adherence remains a significant problem in schizophrenia treatment. Discontinuation of treatment...
Schizophrenia is a relapsing and evolving condition, which requires treatment continuity. Increasing...
AIM & BACKGROUND Non-adherence to antipsychotic treatment is a major issue in the management of seve...
Scientific background. Long-acting injectable antipsychotics (LAIs) are considered one of the most i...
Although response to treatment for the first episode of schizophrenia is generally favourable, nonad...
For many years, long-acting intramuscular (LAI) antipsychotics have been prescribed predominantly to...
AbstractObjectiveAs psychopathology and social functioning can worsen with repeated psychotic episod...
BACKGROUND:For many years, long-acting intramuscular (LAI) antipsychotics have been prescribed predo...
Background/PurposeThe debate on whether long-acting injectable antipsychotic (LAIA) medication is su...